Johnson & Johnson

NYSE-JNJ

Basic

Market Cap
—
EV
—
Shares Out
—
Revenue
$87.7B
Employees
131,900

Margins

Gross
69.39%
EBITDA
34.27%
Operating
26.4%
Pre-Tax
20.1%
Net
16.74%
FCF
23.12%

Returns (5Yr Avg)

ROA
11.89%
ROTA
94.73%
ROE
29.92%
ROCE
17.41%
ROIC
15.87%

Valuation (TTM)

P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—

Valuation (NTM)

Price Target
—
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—

Financial Health

Cash
$20.3B
Net Debt
$15.45B
Debt/Equity
0.51
EBIT/Interest
30.1

Growth (CAGR)

Rev 3Yr
-1.39%
Rev 5Yr
1.43%
Rev 10Yr
1.68%
Dil EPS 3Yr
-3.35%
Dil EPS 5Yr
2.86%
Dil EPS 10Yr
0.01%
Rev Fwd 2Yr
—
EBITDA Fwd 2Yr
—
EPS Fwd 2Yr
—
EPS LT Growth Est
—

Dividends

Yield
—
Payout
79.23%
DPS
$4.86
DPS Growth 3Yr
5.49%
DPS Growth 5Yr
5.61%
DPS Growth 10Yr
5.98%
DPS Growth Fwd 2Yr
—

Metric	Dec '14	Jan '16	Jan '17	Dec '17	Dec '18	Dec '19	Jan '21	Jan '22	Jan '23	Dec '23	LTM
Operating Revenues						82,059	82,584	78,740	79,990	85,159	87,696
Total Revenues						82,059	82,584	78,740	79,990	85,159	87,696
Total Revenues % Chg.						0.6%	0.6%	-4.7%	1.6%	6.5%	4.8%
Cost of Goods Sold, Total						27,556	28,427	23,402	24,596	26,244	26,843
Gross Profit						54,503	54,157	55,338	55,394	58,915	60,853
Selling General & Admin Expenses, Total						21,885	21,731	19,506	19,078	20,166	21,290
R&D Expenses						11,355	12,159	14,277	14,135	15,085	16,414
Other Operating Expenses, Total						33,240	33,890	33,783	33,213	35,251	37,704
Operating Income						21,263	20,267	21,555	22,181	23,664	23,149
Interest Expense, Total						-318	-201	-183	-276	-772	-769
Interest And Investment Income						357	111	53	490	1,261	1,414
Net Interest Expenses						39	-90	-130	214	489	645
Currency Exchange Gains (Loss)						-267	-209	-216	-286	-366	-392
Other Non Operating Income (Expenses)						-3,909	-2,922	-550	1,744	1,664	2,113
EBT, Excl. Unusual Items						17,126	17,046	20,659	23,853	25,451	25,515
Restructuring Charges	—					-266	-247	-209	-275	-798	-346
Merger & Related Restructuring Charges			—	—	—	—	—	—	-300	-200	-1,000
Gain (Loss) On Sale Of Investments	—	—	—	—	—	300	1	—	-700	-600	138
Gain (Loss) On Sale Of Assets						2,154	111	617	380	117	225
Asset Writedown	—					-1,096	-233	-989	-1,216	-1,295	-854
In Process R&D Expenses						-890	-181	-900	-783	-313	-252
Legal Settlements			—	—	—	—	—	—	-900	-6,900	-5,700
Other Unusual Items	—	—	—	—	—	—	—	—	-700	-400	-100
EBT, Incl. Unusual Items						17,328	16,497	19,178	19,359	15,062	17,626
Income Tax Expense						2,209	1,783	1,377	2,989	1,736	2,859
Earnings From Continuing Operations						15,119	14,714	17,801	16,370	13,326	14,767
Earnings Of Discontinued Operations	—	—	—	—	—	—	—	3,077	1,571	21,827	-83
Net Income						15,119	14,714	20,878	17,941	35,153	14,684
Net Income to Common Incl Extra Items						15,119	14,714	20,878	17,941	35,153	14,684
Net Income to Common Excl. Extra Items						15,119	14,714	17,801	16,370	13,326	14,767
Total Shares Outstanding						2,632.5	2,632.5	2,629	2,613.6	2,407.1	2,407.3
Weighted Avg. Shares Outstanding						2,645.1	2,632.8	2,632.1	2,625.2	2,533.5	2,407.4
Weighted Avg. Shares Outstanding Dil						2,684.3	2,670.7	2,674	2,663.9	2,560.4	2,430
EPS						5.7	5.6	7.9	6.8	13.9	6.1
EPS Diluted						5.6	5.5	7.8	6.7	13.7	6
EBITDA						28,272	27,498	28,206	28,510	30,767	30,052
Effective Tax Rate						12.7%	10.8%	7.2%	15.4%	11.5%	16.2%